LENZ data in CMML and AML

Multiple patients in the PREACH-M Phase 2/3 study being completed in Australia have elected to receive LENZ under compassionate use, once their 2 years of therapy per the clinical trial protocol has been completed and the vast majority remain clinically well. All are high-risk patients with RAS and other mutations. In some cases, patients are well beyond 4 years into treatment, longer than would be expected on current standard of care only, although it is important to note this is clinical study data which has been publicly reported,  and LENZ is not approved for marketing in any country at this time.